NCT07733908Not yet recruitingPhase 2
Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer
Efficacy of Posluma PET Scan in Evaulation and Monitoring of Patients Undergoing Focal Therapy for Prostate Cancer
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
To determine the effectiveness of Posluma PET Scan for monitoring prostate cancer patients after targeted treatment, including how accurately it can detect any remaining or returning cancer after about 12 months post-treatment.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- First submitted
- 25 Jul 2026
- Start date
- Aug 2026
- Primary completion date
- Jul 2030
- Lead sponsor
- Aditya Bagrodia
- Diseases
- Prostate cancer
- NCT number
- NCT07733908
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 22
- From Aug 2026 to the primary completion date, Jul 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous Treatment: Prior treatment for PCa, including radiation therapy, chemotherapy, focal therapy, or androgen deprivation therapy.
Other illness
- Severe Comorbid Conditions: Presence of severe comorbid conditions that may interfere with study participation, such as uncontrolled cardiovascular, renal, hepatic, or metabolic diseases.
- Contraindications to Imaging: Known hypersensitivity to components of the Posluma PSMA radiotracer, or inability to undergo PET or MRI imaging due to medical or anatomical constraints (e.g., severe claustrophobia, metallic implants incompatible with MRI).
Who the study is looking for
- Diagnosis: Histologically confirmed PCa.
- Risk Profile: Intermediate-risk , organ-confined PCa
- Eligibility for Focal Therapy: Determined to be an appropriate candidate for focal therapy based on clinical evaluation.
- Age: 18 years or older.
- Life Expectancy: Expected survival of at least 10 years.
- Informed Consent: Ability to understand and willingness to sign the informed consent form.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.